Drug Sales Trends for HYSINGLA ER


Annual Sales Revenues and Units Sold for HYSINGLA ER
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| HYSINGLA ER | ⤷ Start Trial | ⤷ Start Trial | 2022 |
| HYSINGLA ER | ⤷ Start Trial | ⤷ Start Trial | 2021 |
| HYSINGLA ER | ⤷ Start Trial | ⤷ Start Trial | 2020 |
| HYSINGLA ER | ⤷ Start Trial | ⤷ Start Trial | 2019 |
| HYSINGLA ER | ⤷ Start Trial | ⤷ Start Trial | 2018 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
Hysingla ER Market Analysis and Sales Projections
Hysingla ER is a declining, US-focused extended-release hydrocodone product with limited growth potential. Its commercial value depends on continued demand for long-term opioid therapy, Purdue Pharma’s ability to maintain distribution, reimbursement access, and the timing of generic or competing abuse-deterrent hydrocodone products. Hysingla ER sales are not separately disclosed in Purdue’s public financial reporting. The projections below are analyst estimates based on prescription-volume, pricing, and market-contraction assumptions rather than company guidance.
What is Hysingla ER and who markets it?
Hysingla ER contains hydrocodone bitartrate in an extended-release tablet administered once daily. The product is approved for the management of severe pain requiring daily, around-the-clock, long-term opioid treatment when alternative options are inadequate. It is available in strengths from 20 mg to 120 mg and uses abuse-deterrent formulation technology intended to make crushing and dissolution more difficult.[1]
Purdue Pharma received FDA approval for Hysingla ER in December 2014 under NDA 206627.[2] Hydrocodone had already been used in approved medicines, so Hysingla ER did not receive the seven-year new chemical entity exclusivity generally associated with a new active ingredient. Its commercial protection instead depended on formulation patents, regulatory exclusivity, manufacturing know-how, and brand positioning.
| Product attribute | Hysingla ER |
|---|---|
| Active ingredient | Hydrocodone bitartrate |
| Dosage form | Extended-release tablet |
| Administration | Once daily |
| FDA application | NDA 206627 |
| Approval date | December 2014 |
| Sponsor | Purdue Pharma L.P. |
| Therapeutic category | Long-acting opioid analgesic |
| Abuse-deterrent status | FDA-labeled abuse-deterrent properties |
| Primary market | United States |
How large is the Hysingla ER market?
The addressable market is substantially smaller than the total opioid analgesics market. Hysingla ER targets patients requiring chronic, around-the-clock opioid therapy, a segment reduced by tighter prescribing standards, payer controls, opioid litigation, prescription-monitoring programs, and increased use of non-opioid therapies.
The product competes in a narrower segment than immediate-release hydrocodone-acetaminophen products. Relevant competitors include:
- OxyContin, extended-release oxycodone
- Xtampza ER, abuse-deterrent extended-release oxycodone
- Nucynta ER, tapentadol extended release
- Embeda, morphine sulfate and naltrexone extended release
- Generic extended-release morphine
- Generic extended-release oxycodone
- Buprenorphine products used for chronic pain or opioid-use disorder
FDA’s abuse-deterrent labeling gives Hysingla ER a technical distinction, but it does not eliminate overdose, dependence, diversion, or misuse risk. FDA states that abuse-deterrent formulations are expected to reduce certain routes of abuse, not prevent abuse in every circumstance.[3]
Market demand drivers
The main demand drivers are:
- Continued diagnosis of severe chronic pain.
- Patients who require once-daily opioid dosing.
- Physicians seeking an abuse-deterrent extended-release product.
- Reimbursement for branded therapy when generic alternatives are unsuitable.
- Patients who cannot tolerate oxycodone, morphine, or tapentadol.
The market’s structural headwinds are stronger:
- Declining long-term opioid initiation.
- Lower opioid prescribing volumes.
- Mandatory prior authorization.
- Step-therapy requirements.
- State and federal opioid restrictions.
- Payer preference for generic opioids.
- Expanded non-opioid pain-treatment options.
- Contracting and distribution restrictions affecting Purdue products.
What are Hysingla ER sales and revenue projections?
Purdue does not separately report Hysingla ER net sales in publicly available operating disclosures. The following estimates use a modeled US net-sales base and assume continued brand availability with no major generic launch before 2027.
Base-case sales projection
| Year | Estimated net sales | Annual change | Core assumption |
|---|---|---|---|
| 2023A | $45 million | - | Estimated mature branded base |
| 2024E | $41 million | -9% | Lower chronic opioid utilization |
| 2025E | $37 million | -10% | Continued payer and prescribing pressure |
| 2026E | $33 million | -11% | Brand erosion without major generic entry |
| 2027E | $27 million | -18% | Initial generic or competitive pressure |
| 2028E | $21 million | -22% | Broader substitution and formulary restrictions |
| 2029E | $16 million | -24% | Residual branded demand |
Under this base case, Hysingla ER declines at an estimated compound annual rate of approximately 18% from 2024 through 2029.
Scenario analysis
| Scenario | 2025 sales | 2027 sales | 2029 sales | Key assumption |
|---|---|---|---|---|
| Upside | $43 million | $40 million | $35 million | No meaningful generic entry and stable specialty prescribing |
| Base | $37 million | $27 million | $16 million | Gradual erosion and generic pressure beginning in 2027 |
| Downside | $31 million | $15 million | $5 million | Early generic entry, payer exclusion, or distribution disruption |
The upside case does not represent market expansion. It reflects slower erosion of an existing franchise. Hysingla ER is unlikely to achieve material growth without a new indication, stronger reimbursement, a differentiated patient-support program, or a change in prescribing standards.
What drives the sales model?
The model assumes that annual revenue is determined by four variables:
- Number of treated patients.
- Average prescriptions per patient.
- Net price after rebates and discounts.
- Brand retention against generic and therapeutic substitution.
A reasonable commercial framework is:
Net sales = treated patients x annual prescriptions per patient x net price per prescription
The key uncertainty is not list price. It is the number of patients who remain eligible for branded extended-release hydrocodone after payer controls and clinical reassessment. A relatively small decline in chronic opioid patients can produce a disproportionate decline in Hysingla ER revenue because the product has limited non-pain demand.
When does Hysingla ER lose exclusivity?
Hysingla ER’s regulatory exclusivity was limited compared with a new active pharmaceutical ingredient. The product’s commercial protection has primarily depended on listed patents covering controlled-release hydrocodone compositions, abuse-deterrent features, dosage forms, and manufacturing technology.
The FDA Orange Book is the controlling public source for patents and regulatory exclusivity associated with an approved drug.[4] Hysingla ER’s patent position should be assessed by patent family, listed claims, terminal disclaimers, patent-term adjustment, and any pediatric extension. A single “Hysingla expiration date” can be misleading because different patents may expire at different times.
What patents protect Hysingla ER?
Publicly associated Hysingla ER patent families include Purdue-controlled patents directed to:
- Controlled-release hydrocodone formulations.
- High-strength hydrocodone dosage forms.
- Abuse-deterrent tablets.
- Polymer-based release systems.
- Manufacturing and processing methods.
The commercial significance of these patents depends on whether an ANDA applicant can avoid the listed claims through a Paragraph IV certification, wait for patent expiry, or obtain a non-infringing formulation.
Formulation patents are more important to Hysingla ER than method-of-use patents. Chronic pain indications are difficult to protect broadly because opioid-treatment methods often overlap with established medical practice. A formulation patent that covers the tablet’s physical properties or release profile may present a greater technical barrier than a conventional pain-treatment claim.
Are there Paragraph IV challenges to Hysingla ER?
A Paragraph IV challenge would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. An ANDA applicant filing a Paragraph IV certification can trigger patent litigation under the Hatch-Waxman Act if the brand company files suit within the statutory period.[5]
The commercial consequences depend on four events:
- The date of the ANDA filing.
- The patents identified in the certification.
- Whether Purdue files an infringement action.
- Whether the parties reach a settlement establishing an authorized or licensed launch date.
A Paragraph IV filing does not guarantee an early generic launch. Litigation, regulatory deficiencies, manufacturing constraints, and settlement terms can delay entry. Conversely, a successful invalidity or non-infringement decision can materially accelerate generic competition.
Public commercial information does not establish a reliable, current list of all active Hysingla ER ANDA challengers, their proposed launch dates, or settlement terms. The relevant risk remains material because the product has a relatively concentrated revenue base and limited non-brand differentiation.
What is the FDA regulatory status of Hysingla ER?
Hysingla ER remains an FDA-approved extended-release hydrocodone product under NDA 206627. Its label includes boxed warnings addressing addiction, abuse, misuse, life-threatening respiratory depression, accidental ingestion, neonatal opioid withdrawal syndrome, and risks associated with benzodiazepines or other central nervous system depressants.[1]
The FDA’s abuse-deterrent designation does not provide a separate exclusivity period. It can support physician and payer differentiation, but the commercial effect is limited when payers prioritize low-cost generic opioids or when prescribers avoid long-acting opioids as a class.
Hysingla ER is not a biologic. Biosimilar risk therefore does not apply. The relevant competitive threat is ANDA-based generic substitution, not a 351(k) biosimilar application.
How strong is the Hysingla ER patent estate?
Strengths
- Abuse-deterrent formulation claims may require specialized manufacturing and testing.
- High-strength, once-daily hydrocodone tablets are technically distinct from standard immediate-release products.
- Formulation complexity may reduce the number of viable generic entrants.
- Patents covering physical properties can create design-around costs.
Weaknesses
- Hydrocodone is an established active ingredient.
- The product has no durable new-chemical-entity exclusivity.
- Opioid formulation patents face invalidity and obviousness risks.
- Generic applicants can challenge patents without duplicating every branded feature.
- Commercial demand is declining independently of patent expiry.
- The product’s abuse-deterrent characteristics may not justify a substantial premium for payers.
Overall, Hysingla ER has a moderate technical barrier but a weaker commercial moat. Its patent estate may delay direct substitution, yet it cannot reverse the decline in the underlying long-acting opioid market.
What generic launch risks exist?
The most likely launch paths are:
| Launch scenario | Commercial effect |
|---|---|
| No generic before patent expiry | Gradual branded decline continues |
| One approved generic | 30% to 50% first-year revenue reduction |
| Two or more generics | 50% to 75% reduction within 12 to 24 months |
| Authorized generic | Faster price erosion but potentially retained supply economics |
| Competing abuse-deterrent product | Loss of specialty prescriber share without full generic substitution |
| Manufacturing or distribution interruption | Immediate prescription and account losses |
A conventional generic may not be therapeutically identical in abuse-deterrent performance, but it can still pressure utilization if pharmacists and payers treat the products as substitutable. The largest risk is formulary-driven substitution rather than clinical displacement.
Which companies challenge Hysingla ER commercially?
The primary competitive pressure comes from companies selling extended-release oxycodone, morphine, tapentadol, buprenorphine, and generic opioid products. Relevant commercial participants include Purdue Pharma, Collegium Pharmaceutical, Endo, Hikma Pharmaceuticals, Mallinckrodt, Amneal Pharmaceuticals, Teva Pharmaceutical Industries, and other generic manufacturers.
Collegium’s Xtampza ER is the most direct branded abuse-deterrent comparison because it is an extended-release opioid with product differentiation based on formulation technology. OxyContin remains a major reference product in the extended-release opioid category, although its market position has also been affected by opioid restrictions and generic competition.[6]
What is the commercial outlook for Hysingla ER?
Hysingla ER is best viewed as a cash-generating but declining specialty product. Its value is tied to residual branded prescriptions, not market expansion. A buyer or licensee would need to underwrite:
- Remaining patent life by claim and jurisdiction.
- Actual net price and rebate exposure.
- Prescription volume by strength.
- Medicaid and commercial payer coverage.
- Purdue’s distribution continuity.
- ANDA litigation and settlement status.
- Manufacturing compliance and supply reliability.
- Product-liability and opioid-related legal exposure.
The base case supports annual US net sales of roughly $16 million by 2029. A generic launch before 2027 could reduce that figure to below $10 million. If patent protection remains effective and Purdue maintains favorable access, revenue could remain above $30 million through 2029, but that outcome requires slower-than-expected market erosion.
Key Takeaways
- Hysingla ER is a branded, once-daily, abuse-deterrent extended-release hydrocodone product approved in 2014.
- Its addressable market is shrinking because of opioid-prescribing restrictions and payer controls.
- Purdue does not separately disclose Hysingla ER sales.
- A modeled base case estimates $41 million in 2024 net sales, declining to $16 million by 2029.
- The main intellectual-property protection comes from formulation and abuse-deterrent patents, not new-chemical-entity exclusivity.
- Generic substitution is the primary commercial risk; biosimilar risk does not apply.
- The product has moderate formulation complexity but a limited long-term commercial moat.
- Xtampza ER, OxyContin, generic extended-release opioids, tapentadol, and buprenorphine products are the principal competitive alternatives.
FAQs
Is Hysingla ER still commercially relevant?
Yes, but as a declining niche product. Its relevance depends on chronic-pain patients who require once-daily extended-release hydrocodone and retain branded reimbursement.
Does Hysingla ER have abuse-deterrent FDA labeling?
Yes. FDA labeling describes physical and chemical properties intended to make certain forms of manipulation and abuse more difficult.[1]
Can a generic company launch Hysingla ER before every patent expires?
Potentially. A generic applicant may prevail in Paragraph IV litigation, obtain a settlement license, or design around specific formulation claims.
Is Hysingla ER protected by orphan-drug exclusivity?
No. Hysingla ER is not an orphan-designated product, and its primary regulatory protection does not come from orphan exclusivity.
Is Hysingla ER revenue exposed to Purdue Pharma’s restructuring?
Yes. Purdue’s bankruptcy and restructuring have created ongoing commercial, distribution, contracting, and legal considerations for products marketed under the Purdue portfolio.[7]
References
- U.S. Food and Drug Administration. (2024). Hysingla ER prescribing information.
- U.S. Food and Drug Administration. (2014). FDA approves Hysingla ER with abuse-deterrent properties.
- U.S. Food and Drug Administration. (2020). Abuse-deterrent opioid analgesics: Evaluation and labeling.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984.
- U.S. Food and Drug Administration. (2024). Approved drug product labeling for extended-release opioid analgesics.
- U.S. Bankruptcy Court for the Southern District of New York. (2022). In re Purdue Pharma L.P., Chapter 11 proceedings.
More… ↓
